知镜 Cognispect · 医学文献与研究工作台

Frespaciguat (MK-5475): A Novel Inhaled Soluble Guanylate Cyclase Stimulator for Pulmonary Hypertension Associated with COPD.

Whitehead A, Berger R, Zhang Y, Ornoski O, Kim H, Cox JM, Struthers M, Wilkinson H, Zamlynny B, Garcia-Calvo M, Wong K, Kunkel J, House A, Mauser P, Shepherd C, Shen X, Metzger J, Leschek JL, Buist N, McCabe Dunn JM, Lee AY, Xu SS, Pang J, Cabal A, Wylie J, Pereira A, Salituro G, Marsh D, Johnson T, Bauman D, Raghavan S.
Journal of medicinal chemistry · 2026-10-01 · PMID 42911714

文献摘要

Soluble guanylate cyclase (sGC) stimulators are a validated therapeutic approach for pulmonary vasodilation; however, oral agents can cause systemic hypotension and may worsen ventilation-perfusion mismatch in pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). To address these limitations, we applied a property-driven medicinal chemistry strategy to develop an inhaled sGC stimulator that maximizes pulmonary exposure while minimizing systemic exposure. Structure-activity relationship and pharmacokinetic studies identified high systemic clearance and low permeability as key determinants of pulmonary selectivity. These insights led to the discovery of compound 15 (frespaciguat, MK-5475), a subnanomolar sGC stimulator with a prolonged target residence time and >200-fold unbound lung-to-plasma exposure following inhalation. In a rat chronic hypoxia-induced PH model, frespaciguat produced dose-dependent reductions in pulmonary arterial pressure with minimal systemic hemodynamic effects and pharmacodynamic activity persisting >24 h after a single dose. These findings and early clinical data support the development of frespaciguat as an inhaled pulmonary-selective sGC stimulator for PH-COPD.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。